Health 2.0 Europe 2011 - Registration is Now Open

27 - 28 October 2011, Berlin, Germany.
Health 2.0 Europe integrates the best of European web/mobile based technologies, and compares, contrasts and contextualizes them with leading examples of Health 2.0 from around the world. You will see what works in the context of Europe's evolving healthcare systems, and what the "boundary-less" online world means for consumers and physicians working in distinct healthcare systems - all in our lauded format of "rapid-fire" technology demos, provocative keynotes, and interactive discussions.

2011 themes will include:

  • Patient and physician social networks
  • Search & content
  • Communities and data production
  • Consumer and provider tools
  • Health promotion, behavior change and Wellness 2.0
  • Data utility layer & tools
  • System integration
  • Health 2.0 financing
  • Cloud computing and unplatforms

There'll also be a presentation of the latest thinking about Health 2.0 in the European context, special videos, and an unconference session.

A signature of the Health 2.0 conferences, Launch!, will be back by popular demand. Come witness live demos of debuting technologies that will shape the future of healthcare.

Registration to the 2nd annual Health 2.0 Europe Conference is now open. Prices increase on August 15th, so don't wait till it's too late: get your ticket today and save up to 400€.

For further information, please visit:
http://www.health2con.com/europe/

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Roche's personalised medicine entrectinib shrank t…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adole...